MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Capricor Therapeutics EPS Ratio 2011-2026 | CAPR
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Capricor Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.83 | -1.18 | -0.87 | -0.88 | -2.06 | -5.17 | 0.1 | -1.01 | -0.81 | -0.53 | -0.85 | -0.04 | -0.13 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 0.1 | -5.17 | -1.1 |
Quarterly EPS Ratio Capricor Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.54 | -0.57 | -0.53 | - | -0.38 | -0.35 | -0.31 | - | -0.25 | -0.29 | -0.31 | - | -0.26 | -0.29 | -0.32 | - | -0.17 | -0.21 | -0.23 | - | -0.2 | -0.23 | -0.3 | - | -0.43 | -0.59 | -0.75 | - | -1.35 | -1.42 | -0.14 | - | -0.12 | -0.16 | -0.17 | - | -0.29 | -0.26 | -0.26 | - | -0.18 | -0.19 | -0.23 | - | -0.13 | -0.13 | -0.1 | - | -0.15 | -0.16 | -0.14 | - | -0.01 | -0.01 | -0.02 | - | -0.03 | -0.03 | -0.03 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -0.01 | -1.42 | -0.294 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M |  Germany |
 |
Alector
ALEC
|
-1.39 | $ 2.13 | -12.55 % | $ 219 M |  USA |
 |
Acer Therapeutics
ACER
|
-1.66 | - | 2.71 % | $ 14 M | USA |
 |
BioCardia
BCDA
|
-0.55 | $ 1.37 | 6.2 % | $ 29 M | USA |
 |
Black Diamond Therapeutics
BDTX
|
-1.27 | $ 2.4 | -2.83 % | $ 132 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-0.12 | $ 2.8 | -1.06 % | $ 908 M |  Israel |
 |
I-Mab
IMAB
|
-7.66 | - | - | $ 866 M |  China |
 |
BioXcel Therapeutics
BTAI
|
-23.5 | $ 1.64 | -1.8 % | $ 4.16 M | USA |
 |
AgeX Therapeutics
AGE
|
-13.7 | - | -10.17 % | $ 12.2 K | USA |
 |
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B | USA |
 |
BeyondSpring
BYSI
|
-0.28 | $ 1.44 | 6.3 % | $ 58.1 M | USA |
 |
Cabaletta Bio
CABA
|
-1.65 | $ 3.34 | 0.6 % | $ 3.9 M | USA |
 |
AbCellera Biologics
ABCL
|
-0.49 | $ 3.7 | 2.49 % | $ 1.11 B |  Canada |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | USA |
 |
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Codexis
CDXS
|
-0.89 | $ 1.05 | 3.47 % | $ 77.1 M | USA |
 |
Cerus Corporation
CERS
|
-0.11 | $ 2.6 | 1.56 % | $ 480 M | USA |
 |
Certara
CERT
|
-0.01 | $ 7.17 | 1.27 % | $ 1.15 B | USA |
 |
Cullinan Management
CGEM
|
2.46 | $ 15.91 | 2.65 % | $ 931 M | USA |
 |
Compugen Ltd.
CGEN
|
-0.16 | $ 2.28 | 25.97 % | $ 204 M | Israel |
 |
ARCA biopharma
ABIO
|
-3.87 | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
-204 | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
-0.79 | - | 4.01 % | $ 150 M | Canada |
 |
Coherus BioSciences
CHRS
|
-2.53 | $ 1.66 | -0.9 % | $ 156 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-6.62 | - | - | $ 86.2 M | USA |
 |
AIkido Pharma
AIKI
|
-2.38 | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
-3.75 | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-2.52 | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-1.77 | - | -0.23 % | $ 916 M | USA |
 |
Cellectis S.A.
CLLS
|
-2.55 | $ 3.88 | - | $ 116 M | France |
 |
Allena Pharmaceuticals
ALNA
|
-0.72 | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
-3.51 | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-11.7 | - | 4.14 % | $ 49.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-1.73 | - | - | $ 2.17 B | USA |
 |
Aeterna Zentaris
AEZS
|
-0.07 | - | 5.93 % | $ 314 M | Canada |
 |
Ampio Pharmaceuticals
AMPE
|
-10.7 | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-3.25 | - | - | $ 10.1 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-38.9 | $ 3.1 | -0.44 % | $ 1.18 M | USA |
 |
Aravive
ARAV
|
-2.1 | - | -13.39 % | $ 1.45 M | USA |
 |
Cocrystal Pharma
COCP
|
-1.72 | $ 1.02 | -0.97 % | $ 10.4 M | USA |
 |
Aptose Biosciences
APTO
|
-36.4 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-0.96 | - | -39.0 % | $ 4.57 M | USA |
 |
Collegium Pharmaceutical
COLL
|
0.54 | $ 42.0 | 0.79 % | $ 1.33 B | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
0.95 | $ 35.61 | -0.25 % | $ 3.7 B | USA |
 |
Athira Pharma
ATHA
|
-2.52 | - | - | $ 269 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-1.62 | - | 17.91 % | $ 11.1 M | USA |